Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a new vaccine stop genital herpes? early trial underway

NCT ID NCT05432583

First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 31 times

Summary

This early-stage trial tests an investigational vaccine designed to prevent genital herpes lesions caused by HSV-2 (and possibly HSV-1). About 318 adults aged 18–55 will receive different doses of the vaccine or a placebo to check safety and immune response. The study is active but not recruiting, and results will help determine if the vaccine is safe and worthy of further testing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENITAL HERPES SIMPLEX TYPE 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Accellacare PMG Research Wilmington LLC

    Wilmington, North Carolina, 28401, United States

  • Accellacare Raleigh Medical Group

    Raleigh, North Carolina, 27609, United States

  • Alliance for Multispecialty Research, LLC

    Tempe, Arizona, 85281, United States

  • CTI Clinical Research Center

    Cincinnati, Ohio, 45212, United States

  • Great Lakes Clinical Trials - Flourish Research

    Chicago, Illinois, 60640, United States

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

Conditions

Explore the condition pages connected to this study.